We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
Read MoreHide Full Article
Fresenius Medical Care AG& Co (FMS - Free Report) announced the launch of the newest version of its home dialysis machine, NxStage Versi HD, with GuideMe Software. This new system simplifies treatment, enhances user experience and accelerates training. The company stated that it has reached a key milestone with over 14,000 United States patients using its NxStage system for Home Hemodialysis (HHD).
Following the announcement on Sept. 4, shares of the company were up 1% as of Sept. 6.
Significance of Fresenius Medical Care’s NxStage VersiHD
The NxStage VersiHD with GuideMe Software introduces advanced features to simplify HHD, making it easier for patients and care partners to learn and retain skills. Its pictorial-based guidance system ensures ease of use, enhancing confidence and training speed. With 18% growth in new patients from January to April 2024, the adoption of this system represents a major step forward in delivering high-quality home-based care.It highlights Fresenius Medical Care's ongoing commitment to innovation, improving the lives of patients by offering safe, convenient and flexible home dialysis solutions.
More on NxStage VersiHD
Since its FDA clearance in 2023, Fresenius Medical Care’s NxStage VersiHD with GuideMe Software has gained significant traction across the United States, with large and independent dialysis providers adopting the system.
This user-friendly interface accommodates various learning styles and reduces training time by 7-10 days. With a full U.S. rollout underway, global expansion is planned in the coming years.
Market Prospects Favoring FMS
Per a report in Precedence Research, the global home dialysis systems market is estimated to be worth $23.55 billion in 2024. It is anticipated to reach $57.20 billion by 2033 at a CAGR of 10.36%.
The robust growth is likely to be driven by the increasing demand for home dialysis and the rising number of kidney diseases.
Recent Development at Fresenius Medical Care
In May, Fresenius Medical Care, through its affiliate Liberty Dialysis Hawaii, opened Windward O'ahu's first home hemodialysis training center. This facility in Kailua expands access to kidney disease treatment by offering hands-on training with NxStage portable dialysis systems, providing patients with flexible home-based care options. The system also ensures uninterrupted treatment during emergencies, reinforcing Fresenius' commitment to innovative kidney care solutions.
FMS Stock Price Performance
Shares of Fresenius Medical Care have lost 5.5% year to date against the industry’s 7.3% growth. The S&P 500 has witnessed a 13.3% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Fresenius Medical Care carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , ABM Industries (ABM - Free Report) and Quest Diagnostics (DGX - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth year to date.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have risen 3.7% year to date compared with the industry’s 10.2% growth.
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% year to date compared with the industry’s 11.9% growth.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
Fresenius Medical Care AG& Co (FMS - Free Report) announced the launch of the newest version of its home dialysis machine, NxStage Versi HD, with GuideMe Software. This new system simplifies treatment, enhances user experience and accelerates training. The company stated that it has reached a key milestone with over 14,000 United States patients using its NxStage system for Home Hemodialysis (HHD).
Following the announcement on Sept. 4, shares of the company were up 1% as of Sept. 6.
Significance of Fresenius Medical Care’s NxStage VersiHD
The NxStage VersiHD with GuideMe Software introduces advanced features to simplify HHD, making it easier for patients and care partners to learn and retain skills. Its pictorial-based guidance system ensures ease of use, enhancing confidence and training speed. With 18% growth in new patients from January to April 2024, the adoption of this system represents a major step forward in delivering high-quality home-based care.It highlights Fresenius Medical Care's ongoing commitment to innovation, improving the lives of patients by offering safe, convenient and flexible home dialysis solutions.
More on NxStage VersiHD
Since its FDA clearance in 2023, Fresenius Medical Care’s NxStage VersiHD with GuideMe Software has gained significant traction across the United States, with large and independent dialysis providers adopting the system.
This user-friendly interface accommodates various learning styles and reduces training time by 7-10 days. With a full U.S. rollout underway, global expansion is planned in the coming years.
Market Prospects Favoring FMS
Per a report in Precedence Research, the global home dialysis systems market is estimated to be worth $23.55 billion in 2024. It is anticipated to reach $57.20 billion by 2033 at a CAGR of 10.36%.
The robust growth is likely to be driven by the increasing demand for home dialysis and the rising number of kidney diseases.
Recent Development at Fresenius Medical Care
In May, Fresenius Medical Care, through its affiliate Liberty Dialysis Hawaii, opened Windward O'ahu's first home hemodialysis training center. This facility in Kailua expands access to kidney disease treatment by offering hands-on training with NxStage portable dialysis systems, providing patients with flexible home-based care options. The system also ensures uninterrupted treatment during emergencies, reinforcing Fresenius' commitment to innovative kidney care solutions.
FMS Stock Price Performance
Shares of Fresenius Medical Care have lost 5.5% year to date against the industry’s 7.3% growth. The S&P 500 has witnessed a 13.3% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Fresenius Medical Care carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , ABM Industries (ABM - Free Report) and Quest Diagnostics (DGX - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth year to date.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have risen 3.7% year to date compared with the industry’s 10.2% growth.
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% year to date compared with the industry’s 11.9% growth.